At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 300 target
Drug / intervention
The KPCXM18 injection +2 moredrug
Likely dose
The KPCXM18 injection 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase Ⅱb Clinical Trial to Evaluate the Efficacy and Safety of the KPCXM18 Injection at Different Doses in The Treatment of Acute Ischemic Stroke
In Brief
A Phase 2 clinical trial evaluating The KPCXM18 injection and Placebo for Acute Ischemic Stroke. Currently recruiting, targeting 300 participants across 23 sites.
Signals
Enrolling ahead of pace
Detailed Summary
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2026
Enrollment StartNov 2025
First PostedDec 2025
TodayJul 2026
Primary CompletionOct 2026
First PostedDec 12, 2025
Enrollment StartNov 22, 2025
Primary CompletionOct 18, 2026
TodayJul 1, 2026
Enrollment to primary: 11 monthsPosted 7 months agoPrimary completion in 4 months
Interventions
The KPCXM18 injectiondrug
Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 12±2 days.
Placebodrug
Intravenous infusion twice a day with an interval of 12±2 hours for 12±2 days.
The KPCXM18 injectiondrug
Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 12±2 days.